An Open Label, Multiple Centers Phase Ib/II Study of APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Latest Information Update: 16 Aug 2024
At a glance
- Drugs APG 1387 (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ascentage Pharma
- 14 Aug 2024 Planned End Date changed from 1 Dec 2024 to 31 Dec 2024.
- 14 Aug 2024 Planned primary completion date changed from 1 Jun 2024 to 31 Dec 2024.
- 27 Mar 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.